Cao Pharmaceuticals is an early clinical stage oncology drug development company with a rich and deep history. We are committed to develop highly effective drugs from a natural plant extract with very low or readily manageable toxicity for the treatment of all solid tumors (i.e. colon, lung, breast, prostrate, melanoma, sarcoma, pancreatic, liver, etc.) and lymphoma. And with much shorter development timeframes compared to traditional chemotherapies.. Cao Pharmaceuticals is currently conducting a Phase I trial with their lead drug. And Phase II trials are scheduled to start Q1 2018.
Design, develop and manufacture new anticancer drugs
Clinical trial management